سعر كلير اير 4 مجم 7 أكياس 2025

Montelukast 4 mg oral granules in sachets by Amoun (Egypt), pack of 7 sachets.

• Prophylaxis and chronic treatment of asthmaPopulation: Patients 12 months of age and older (formulation-dependent)DailyMed (U.S. NLM)
• Prevention of exercise-induced bronchoconstriction (EIB)Population: Patients 6 years of age and older (chewable/tablet as age-appropriate)DailyMed (U.S. NLM)
• Relief of allergic rhinitis symptoms (seasonal/perennial) when alternatives inadequatePopulation: Age-dependent per US labelDailyMed (U.S. NLM)

• Most common adverse reactions (≥5% and greater than placebo): upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, otitis.International label, equivalent formulation · DailyMed (U.S. NLM)

• Hypersensitivity to montelukast or any component of the formulation.International label, equivalent formulation · DailyMed (U.S. NLM)

• Boxed warning: serious neuropsychiatric events (agitation, aggression, depression, sleep disturbances, suicidal thoughts/behaviour) have been reported; discuss benefits/risks; discontinue and seek care if such symptoms occur; for allergic rhinitis reserve for inadequate response/intolerance to alternatives.International label, equivalent formulation · DailyMed (U.S. NLM)
• Not for acute asthma attacks (including status asthmaticus); keep rescue short-acting β-agonist available; do not abruptly substitute for inhaled/oral corticosteroids.International label, equivalent formulation · DailyMed (U.S. NLM)
• Patients with known aspirin sensitivity should continue to avoid aspirin/NSAIDs; SINGULAIR chewable tablets contain phenylalanine (aspartame) — relevant in phenylketonuria.International label, equivalent formulation · DailyMed (U.S. NLM)

• Theophylline, prednisone/prednisolone, oral contraceptives, digoxin, warfarin, gemfibrozil, itraconazole, CYP inducers (e.g. phenobarbital, rifampin)US label: no dose adjustment generally needed for listed co-administrations; gemfibrozil increased montelukast exposure ~4.4-fold (clinical experience still supports no routine dose change); phenobarbital reduced montelukast AUC ~40%.DailyMed (U.S. NLM)

• Available published cohort data over decades with montelukast in pregnancy have not established a drug-associated risk of major birth defects; animal data at high exposures showed no adverse developmental effects.General active-ingredient information · DailyMed (U.S. NLM)
• Montelukast is present in human milk; available data do not suggest a significant risk of adverse reactions in breastfed infants; effects on milk production unknown.General active-ingredient information · DailyMed (U.S. NLM)

• Montelukast: Orally active, selective antagonist of the cysteinyl leukotriene type-1 (CysLT1) receptor, blocking LTD4-mediated airway oedema, smooth-muscle contraction and inflammation (SINGULAIR US label).